Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Vermersch

Showing results (91-100 of 250) with videos related to

Pageof 25
Sort By:
Neurology and Therapy|June 29, 2023
Expert Narrative Review of the Safety of Cladribine Tablets for the Management of Relapsing Multiple SclerosisPierre Clavelou, Giovanni Castelnovo, Valérie Pourcher, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 4, 2018
Optic nerve double inversion recovery hypersignal in patients with clinically isolated syndrome is associated with asymptomatic gadolinium-enhanced lesionFrédéric London, Hélène Zéphir, Nawal Hadhoum, et al.
The Lancet. Neurology|March 15, 2011
Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysisGavin Giovannoni, Stuart Cook, Kottil Rammohan, et al.
Multiple Sclerosis and Related Disorders|April 17, 2015
Cladribine tablets for relapsing-remitting multiple sclerosis: Efficacy across patient subgroups from the phase III CLARITY studyKottil Rammohan, Gavin Giovannoni, Giancarlo Comi, et al.
Molecules (Basel, Switzerland)|September 13, 2025
Discovery of Novel Benzamide-Based Sigma-1 Receptor Agonists with Enhanced Selectivity and SafetyPascal Carato, Bénédicte Oxombre, Séverine Ravez, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 29, 2016
The clinical perspective: How to personalise treatment in MS and how may biomarkers including imaging contribute to this?Patrick Vermersch, Thomas Berger, Ralf Gold, et al.
Frontiers in Immunology|January 10, 2022
Integrated Lymphopenia Analysis in Younger and Older Patients With Multiple Sclerosis Treated With Cladribine TabletsGavin Giovannoni, Patricia K Coyle, Patrick Vermersch, et al.
Multiple Sclerosis and Related Disorders|May 30, 2020
Teriflunomide vs injectable disease modifying therapies for relapsing forms of MSPatrick Vermersch, Jiwon Oh, Mark Cascione, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 19, 2018
Magnetic resonance imaging changes following natalizumab discontinuation in multiple sclerosis patients with progressive multifocal leukoencephalopathyJérôme Hodel, Blanche Bapst, Olivier Outteryck, et al.
Journal of Neuroimmunology|November 14, 2006
Changes in self-reactive IgG antibody repertoire after treatment of experimental autoimmune encephalomyelitis with anti-allergic drugsMohamed El Behi, Hélène Zéphir, Didier Lefranc, et al.
Pageof 25

Showing results (91-100 of 250) with videos related to

Sort By:
Pageof 25
Neurology and Therapy|June 29, 2023
Expert Narrative Review of the Safety of Cladribine Tablets for the Management of Relapsing Multiple SclerosisPierre Clavelou, Giovanni Castelnovo, Valérie Pourcher, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 4, 2018
Optic nerve double inversion recovery hypersignal in patients with clinically isolated syndrome is associated with asymptomatic gadolinium-enhanced lesionFrédéric London, Hélène Zéphir, Nawal Hadhoum, et al.
The Lancet. Neurology|March 15, 2011
Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysisGavin Giovannoni, Stuart Cook, Kottil Rammohan, et al.
Multiple Sclerosis and Related Disorders|April 17, 2015
Cladribine tablets for relapsing-remitting multiple sclerosis: Efficacy across patient subgroups from the phase III CLARITY studyKottil Rammohan, Gavin Giovannoni, Giancarlo Comi, et al.
Molecules (Basel, Switzerland)|September 13, 2025
Discovery of Novel Benzamide-Based Sigma-1 Receptor Agonists with Enhanced Selectivity and SafetyPascal Carato, Bénédicte Oxombre, Séverine Ravez, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 29, 2016
The clinical perspective: How to personalise treatment in MS and how may biomarkers including imaging contribute to this?Patrick Vermersch, Thomas Berger, Ralf Gold, et al.
Frontiers in Immunology|January 10, 2022
Integrated Lymphopenia Analysis in Younger and Older Patients With Multiple Sclerosis Treated With Cladribine TabletsGavin Giovannoni, Patricia K Coyle, Patrick Vermersch, et al.
Multiple Sclerosis and Related Disorders|May 30, 2020
Teriflunomide vs injectable disease modifying therapies for relapsing forms of MSPatrick Vermersch, Jiwon Oh, Mark Cascione, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 19, 2018
Magnetic resonance imaging changes following natalizumab discontinuation in multiple sclerosis patients with progressive multifocal leukoencephalopathyJérôme Hodel, Blanche Bapst, Olivier Outteryck, et al.
Journal of Neuroimmunology|November 14, 2006
Changes in self-reactive IgG antibody repertoire after treatment of experimental autoimmune encephalomyelitis with anti-allergic drugsMohamed El Behi, Hélène Zéphir, Didier Lefranc, et al.
Pageof 25